Development of an AIDS vaccine using Sendai virus vectors

被引：16
|
作者：
Ishii, Hiroshi [1 ]
Matano, Tetsuro [1 ,2 ]
机构：
[1] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan
[2] Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan
来源：
VACCINE | 2015年 / 33卷 / 45期
关键词：
AIDS vaccine; Sendai virus vector; HIV; SIV; CD4(+) T-CELLS; LYMPHOCYTE-BASED CONTROL; IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSES; HIV-1; VACCINE; REPLICATION; INFECTION; IMMUNOGENICITY;
D O I：
10.1016/j.vaccine.2015.06.114
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Development of an effective AIDS vaccine is crucial for the control of global human immunodeficiency virus type 1 (HIV-1) prevalence. We have developed a novel AIDS vaccine using a Sendai virus (SeV) vector and investigated its efficacy in a macaque AIDS model of simian immunodeficiency virus (SIV) infection. Its immunogenicity and protective efficacy have been shown, indicating that the SeV vector is a promising delivery tool for AIDS vaccines. Here, we describe the potential of SeV vector as a vaccine antigen delivery tool to induce effective immune responses against HIV-1 infection. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6061 / 6065
页数：5
相关论文
共 50 条
  • [1] Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas Implications for AIDS vaccine development using Sendai virus vectors
    Hara, Hiroto
    Hironaka, Takashi
    Inoue, Makoto
    Iida, Akihiro
    Shu, Tsugumine
    Hasegawa, Mamoru
    Nagai, Yoshiyuki
    Falsey, Ann R.
    Kamali, Anatoli
    Anzala, Omu
    Sanders, Eduard J.
    Karita, Etienne
    Mwananyanda, Lawrence
    Vasan, Sandhya
    Lombardo, Angela
    Parks, Christopher L.
    Sayeed, Eddy
    Krebs, Marietta
    Cormier, Emmanuel
    Ackland, James
    Price, Matthew A.
    Excler, Jean-Louis
    [J]. HUMAN VACCINES, 2011, 7 (06): : 639 - 645
  • [2] Sendai-specific neutralizing antibody prevalence in different geographic populations: implications for AIDS vaccine development with Sendai vectors
    Excler, J.
    Hara, H.
    Hironaka, T.
    Inoue, M.
    Iida, A.
    Shu, T.
    Hasegawa, M.
    Nagai, Y.
    Matano, T.
    Lombardo, A.
    Parks, C.
    Sayeed, E.
    Ackland, J.
    Price, M.
    Cormier, E.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A123 - A123
  • [3] Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses
    Seki, Sayuri
    Matano, Tetsuro
    [J]. EXPERT REVIEW OF VACCINES, 2016, 15 (01) : 119 - 127
  • [4] Live recombinant vectors for AIDS vaccine development
    Voltan, R
    Robert-Guroff, M
    [J]. CURRENT MOLECULAR MEDICINE, 2003, 3 (03) : 273 - 284
  • [5] Vaccine development using the simian immunodeficiency virus model for AIDS
    Norley, S
    Beer, B
    Binninger-Schinzel, D
    Vogel, T
    Hohn, O
    Seibold, E
    Radke, D
    Cosma, C
    Kurth, R
    [J]. INTERVIROLOGY, 2002, 45 (4-6) : 267 - 274
  • [6] USE OF VACCINIA VIRUS VECTORS FOR DEVELOPMENT OF AIDS VACCINES
    MOSS, B
    [J]. AIDS, 1988, 2 : S103 - S105
  • [7] Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
    Nakanishi, Mahito
    Otsu, Makoto
    [J]. CURRENT GENE THERAPY, 2012, 12 (05) : 410 - 416
  • [8] Sendai virus vectors Pushing the envelope in the lung
    Flotte, T. R.
    [J]. GENE THERAPY, 2011, 18 (02) : 107 - 108
  • [9] Gene transfer vectors based on Sendai virus
    Nakanishi, M
    Mizuguchia, H
    Ashihara, K
    Senda, T
    Akuta, T
    Okabe, J
    Nagoshi, E
    Masago, A
    Eguchi, A
    Suzuki, Y
    Inokuchi, H
    Watabe, A
    Ueda, S
    Hayakawa, T
    Mayumi, T
    [J]. JOURNAL OF CONTROLLED RELEASE, 1998, 54 (01) : 61 - 68
  • [10] Hepatotropic transduction by Sendai virus vectors.
    Bitzer, M
    Leyrer, S
    Sedlmeier, R
    Spiegel, M
    Gregor, M
    Neubert, WJ
    Lauer, U
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : A1213 - A1213
12345